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Abstract: Extracellular vesicles (EVs) represent a heterogeneous group of membranous structures
shed by all kinds of cell types, which are released into the surrounding microenvironment or spread to
distant sites through the circulation. Therefore, EVs are key mediators of the communication between
tumor cells and the surrounding microenvironment or the distant premetastatic niche due to their
ability to transport lipids, transcription factors, mRNAs, non-coding regulatory RNAs, and proteins.
Multiple myeloma (MM) is a hematological neoplasm that mostly relies on the bone marrow (BM).
The BM represents a highly supportive niche for myeloma establishment and diffusion during the
formation of distant bone lesions typical of this disease. This review represents a survey of the most
recent evidence published on the role played by EVs in supporting MM cells during the multiple
steps of metastasis, including travel and uptake at distant premetastatic niches, MM cell engraftment
as micrometastasis, and expansion to macrometastasis thanks to EV-induced angiogenesis, release of
angiocrine factors, activation of osteolytic activity, and mesenchymal cell support. Finally, we illustrate
the first evidence concerning the dual effect of MM-EVs in promoting both anti-tumor immunity and
MM immune escape, and the possible modulation operated by pharmacological treatments.
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1. Biogenesis and Characteristics of Extracellular Vesicles
Extracellular vesicles (EVs) can be released by all kinds of cell types and are found in most
biological fluids. They are mainly classified according to different features: biogenesis, size, density,
and cargo, which can change depending on EV origin, the overall status of the producing cells, and the
surrounding microenvironment.
In the last years, EVs have emerged as key mediators of the pathological interplay between cancer
cells and the healthy surrounding cells due to their cargo of lipids, transcription factors, mRNAs,
non-coding regulatory RNAs, and proteins [1–3].
EV classification is based on their origin and cargo, and allows the identification of three main
subgroups: (i) exosomes, vesicles with a diameter below 100–150 nm, deriving from the endocytic
compartment; (ii) microvesicles, generated directly by plasma membrane budding and characterized
by a wider size range (100–1000 nm); and (iii) apoptotic bodies, big membranous structures (diameter
> 2000 nm) generated directly from the cytoplasmic membrane upon activation of the apoptotic
cascade [1].
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Exosomes arise from intraluminal vesicles (ILVs) contained in late endosomes or multivesicular
bodies (MVBs). MVBs containing ILVs may then fuse with lysosomes, forming mature lysosomes,
or with the plasma membrane, releasing exosomes [4]. Exosomal cargo is represented by molecules
actively and specifically selected by the endosomal sorting complexes required for transport (ESCRT)
and loaded into the ILVs for subsequent degradation or recycling. Although exosomal content partially
reflects the composition of the producing cells, it is not identical, since it results from the selection
of specific molecules [4]. The fusion of MVB with the cytoplasmic membrane and the consequent
exosome release are characterized by the activation of proteins involved in MVBs’ docking, such as
the actin regulator cortacin, Rab family of GTPases, SNAP receptor (SNARE) proteins, and the fusion
regulator synaptotagmin-7. The biogenesis and release of microvesicles is less characterized, but clearly
involves different components of the same complexes involved in ILV generation. Variation in content
and distribution of lipids that form the plasma membrane may affect the release of microvesicles [5].
Of note, since the current methodologies do not distinguish between exosomes, microvesicles, and
apoptotic bodies, in this review we will use the generic term EVs, which includes all the different
vesicle subtypes.
EVs can affect the features and functions of receiving cells by delivering many different classes
of molecules, such as transcription factors, mRNAs, non-coding regulatory RNAs, and infectious
particles. The content of EV partially reflects the cellular origin. Tumor-derived EVs share with EVs
of different origins a great number of proteins including adhesion molecules such as tetraspanins
and integrins, antigen presenting molecules (MHC class I and II), membrane transport and fusion
molecules (annexins, flotillin, and Rab proteins), cytoskeletal proteins (actin, tubulin, and moesin), and
many others such as heat shock protein 70 (HSP70) [6]. In addition, they express cell-specific molecules
that can often be considered as immunophenotypical markers such as syndecan-1/CD138, a plasma
cell marker characteristic of multiple myeloma cells [7].
2. Multiple Myeloma Cell Dissemination
Multiple myeloma (MM) is a hematological neoplasm deriving from the clonal proliferation
of malignant plasma cells (PCs) [8,9]. MM mostly relies on the tumor microenvironment for its
progression. The bone marrow (BM) represents a highly specialized and supportive myeloma niche.
Within the BM, PCs take advantage of the local healthy cell populations including mesenchymal
stromal cells (MSCs), osteoblasts (OBs), osteoclasts (OCs), endothelial cells, and cells of the immune
system, and are sustained by a very supportive milieu rich in cytokines and growth factors [8,9].
Tumor metastasis is the major cause of death in cancer patients. Furthermore, the spread of
distant bone lesions is a key event in MM progression. Through a process similar to bone metastases
diffusion from primary carcinoma, malignant PCs can recirculate within the blood and finally settle at
different sites where they can create new metastatic lesions. The metastatic process is characterized
by consecutive steps that include colonization and survival of micrometastasis, dormancy, and
finally reactivation and formation of macrometastasis, thereby interfering with physiological bone
homeostasis [10].
BM is the most suitable microenvironment for myeloma cell needs. Therefore, it is not surprising
that malignant PCs mostly reproduce secondary tumor lesions at distant BM skeletal districts [11].
Nonetheless, the BM of MM patients differs in its cellular and non-cellular composition from that
of healthy individuals [12], suggesting that the reprogramming of the distant niche is necessary to
favor MM cell homing. It is well known that the choice of metastatization site is determined by the
primary tumor ability to precondition distant body districts to allow and support metastatic tumor cell
settlement and formation of new tumor lesions. In the following sections we will analyze how EVs
released by MM cells (MM-EVs) contribute to this process to favor MM cell dissemination and the
formation of new bone lesions.
Int. J. Mol. Sci. 2019, 20, 3236 3 of 15
3. EVs Support Myeloma Cell Journey to the Metastatic Site
MM-EVs have been found both in the MM patients’ peripheral blood and BM, and their levels in
the blood circulation are positively correlated with the number of bone lesions [13]. Although this
is not direct evidence that MM-EVs play a role in tumor dissemination, the analysis of EV content
further substantiates this hypothesis. Indeed, EV cargo is enriched with microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs), which promote proliferation and osteolysis—two key events that
occur during premetastatic niche education and metastasis formation [13,14].
Roccaro et al. showed that exosomes produced by BM-MSCs conditioned by MM disease promote
MM cell growth, and are also involved in MM cell dissemination in vivo, a distinct process from
normal BM-MSC-derived exosomes [15].
Recently, several groups analyzed the molecular basis of EV pro-metastatic potential, providing a
better understanding of their contribution to the different steps of MM cell dissemination and to the
development of new lesions. Malignant PCs are initially released from the primary location, protected
by an immunosuppressive environment. After leaving the BM, during their journey in the blood
stream, myeloma cells are exposed to attacks from the immune system and are subjected to shear stress
due to circulation flux. The prevention of tumor metastasis has its major actors in cytotoxic CD8+ T
cells (CTL), natural killer (NK) cells, and non-classical “patrolling” monocytes [16–18]. Recent findings
from Nielsen and colleagues [19] showed that MM-EVs favor MM cell diffusion to distant skeletal sites
thanks to their procoagulant activity (Figure 1).
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Indeed, microvesicles from MM patients exert a procoagulant activity due to both tissue factor
(TF) and procoagulant phospholipids (PPLs), resulting in thrombin generation [19]. Thrombin triggers
platelet activation, polymerizes fibrinogen to fibrin and triggers its crosslinking [20]. The interaction
between platelet/fibrin and tumor cells promotes metastasis formation in different ways: (i) by
providing a cover that protects the neoplastic embolus and possibly newly settled micrometastases
from NK cell-mediated elimination [20]; (ii) by stimulating the extravasation through the upregulation
of adhesion molecules and the increase in endothelial permeability [21–23]; and (iii) by preconditioning
the “metastatic niche” with platelet-derived cytokines such as TGF-β [21]. In MM patients, platelet
activation correlates with disease progression. The crucial role of platelets in MM cell dissemination
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is further supported by evidence that MM cells preconditioned with platelets showed significantly
increased tumor cell engraftment ability in vivo, with a mechanisms dependent on IL-1β release [24].
This cytokine has a pleiotropic effect on MM cell proliferation, in addition to the potential to activate
OCs and the expression of adhesion molecules for extravasation such as integrinα4β1 and CD44 [25,26].
4. EV Uptake and Cargo Delivery to the Premetastatic Niche
A second important step in promoting metastasis formation is EV ability to reach the premetastatic
niche and deliver pro-tumor signals to the local microenvironment. EVs are highly enriched in
cholesterol, annexin, sphingomyelin, glycosphingolipids, and phosphatidylserine, which make them
stable structures released in the interstitial space or into the biological fluids such as blood, thereby
acting on short or long distances and promoting autocrine and paracrine signaling [27].
EV tropism is a property essential to transfer EV cargo to selected recipient cells at distant BM
sites. Increasing lines of evidence suggest that tumor-derived EVs might be uptaken by organ-specific
cells where they can participate in preconditioning the premetastatic niche [28,29].
EV uptake by recipient cells is energy dependent [30]. Several lines of evidence support the
hypothesis that EVs are mostly internalized through clathrin-mediated and caveolin-dependent
endocytosis, at least in part, promoted by ligand/receptor interactions. This interplay seems to be
a cellular-specific mechanism and may lead to the activation of different downstream biological
processes such as signaling transduction, endocytosis, and membrane fusion. Macropinocytosis and
phagocytosis appear to be less frequent [31]. EV uptake may depend on the lipid composition (in
particular, changes in the organization of lipid rafts can modify EV propensity to fuse), and an acidic
microenvironment seems to promote membrane fusion events [27].
Several potential receptors favoring exosome uptake have been identified. These include Tim1/4
for B cells [32] and ICAM-1 for antigen presenting cells (APCs) [33], while heparan sulfate proteoglycans
have been reported as receptors for cancer cell-derived exosomes [34]. Syndecan-1 (CD138) is a cell
surface heparan sulfate-bearing proteoglycan expressed at high levels on MM cells for which it also
represents a selective marker. Syndecan-1 activated by high levels of heparanase in MM cells promotes
the spontaneous metastasis of myeloma cells to the bone [35]. A possible explanation is supported by
syndecan-1 expressed on exosomes, which promotes their uptake by BM-MSCs with a mechanism
based on the ability of fibronectin to bind to heparin sulfate molecules on the membrane surfaces of
both MM-EVs and BM-MSCs [36] (Figure 1).
5. MM-EVs Promote Angiogenesis and Production of Angiocrine Factors
Angiogenesis is a key process in metastasis formation. Besides promoting tumor cell growth
at the primary site and favoring the dissemination of neoplastic cells in the blood circulation [37],
angiogenesis plays a crucial role also in the preparation of the premetastatic niche. Indeed, the high
permeability and leakiness of the newly formed vessels at the metastatic niche favor cancer cell
extravasation from the circulation. Moreover, endothelial cells of new vessels may release angiocrine
factors that nurture tumor cells when reaching the premetastatic niche, thereby supporting the survival
and growth of disseminated tumor cells [38,39]. Nonetheless, a full angiogenic switch is necessary for
the progression of dormant or micrometastatic tumors to macrometastases [40].
Tumor-derived EVs are known to participate in neoangiogenesis and promote endothelial
branching both locally and at distant sites. EVs endowed by angiogenic properties are shed by cells
from different types of tumor, including breast cancer, pancreatic carcinoma, glioblastoma, bladder
cancer, chronic myelogenous leukemia, etc. [41].
Although a complete characterization of MM-EV content remains unavailable, the presence of
several angiogenic factors has been reported, including VEGF, angiogenin, bFGF, Serpin E1, TIMP-1,
and PDGF [42,43]. Accordingly, as shown in Figure 2, MM-EVs can induce endothelial cell proliferation,
tube formation, and new vessel development through the modulation of different pathways such
as c-Jun N-terminal kinase (JNK), signal transducer and activator of transcription 3 (STAT3), and
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p53 [42,43], in addition to promoting the secretion of angiocrine molecules such as VEGF, ICAM-1, and
IL-6 by endothelial cells [44,45].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 15 
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Further studies indicate that components of MM-EV cargo such as CD147 [46], piRNA-823 [45],
and miR-135b [47,48] may also contribute to the angiogenic effects of MM-EVs. In particular, Umezu et
al. demonstrated that exosomal miR-135b directly promotes endothelial tube formation by blocking the
expression of factor-inhibiting hypoxia-inducible factor 1 (FIH-1) in endothelial cells [47,48]. Finally,
besides its role in exosome uptake, MM cell marker syndecan-1/CD138, carried by MM-EVs, plays a
key role in promoting endothelial cell invasion and angiogenesis [49]. This function is consistent with
the correlation of syndecan-1 gene expression and BM microvessel density in patients with monoclonal
gammopathy of uncertain significance (MGUS) and MM [50]. It remains to be investigated if these
mechanisms influence the formation of new vessels at the premetastatic niche.
Interestingly, MM-EVs treated with bortezomib or lenalidomide exhibit decreased ability to
activate NF-κB and to induce VEGF, IL-6, and bFGF expression in endothelial cells, thus showing
decreased angiogenic potential [43,51]. This suggests that these two chemotherapeutics may counteract
MM progression by affecting EV-mediated communication between MM and endothelial cells.
6. MM-EVs Promote the Formation of New Bone Lesions
Bone resorption regulates different aspects of metastasis formation, from the creation of space in
the osseous matrix for tumor cell settlement to the release of entrapped pro-tumor factors, including
TGF-β and insulin-like growth factor (IGF) [52]. OCs account for 1–4% of the total cells in bone and are
responsible for its resorption. In MM bone disease, monocytes [52] and myeloid derived suppressor
cells (MDSCs) are OC sources [53]. During MM progression, the functional balance between OCs and
OBs (cells of mesenchymal origin which synthesize the bone matrix) is definitively perturbed, with an
increase in OC lytic activity [13].
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As illustrated in Figure 3, the first indication of a potential role of MM-EVs in promoting the
dissemination of myeloma bone disease was reported by Zhang et al. who identified a correlation
between peripheral blood CD138+ circulating EVs and bone lesions in de novo MM patients [13].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
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Raimondi et al. also showed that -derived exosomes directly support bone osteolysis by
favoring the migration and differentiation of OC precursors [54]. The authors performed in vitro studies
to demonstrate that MM-derived exosomes contribute to OC migration, by increasing CXC chemokine
receptor type 4 (CXCR4) expression, and promote OC viability by enhancing the anti-apoptotic
gene expression of Bcl-2, survivin, and AKT phosphorylation [54]. Finally, MM-derived exosomes
regulate OC bone resorbing activity by increasing the expression of key osteoclastogenic enzymes,
i.e., tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), and matrix metallopeptidase
9 (MMP9) [54].
Interestingly, external sti uli, such as che otherapeutic treat ents or hypoxia, ay increase
the osteoclastogenic potential of -EVs. Indeed, treat ents with standard-of-care drugs such as
bortezomib, carfilzomib, and melphalan increase the levels of heparanase in MM-derived exosomes [55].
Heparanase activates the ERK pathway resulting in MM cells releasing the osteolytic factors, MMP-9
and receptor activator of nuclear factor-κB ligand (RANKL). Not surprisingly, high levels of heparanase
stimulate systemic osteoclastogenesis and osteolysis [56]. These lines of evidence suggest that drugs
currently used in MM therapy to inhibit tumor growth and bone disease may contemporaneously
ignite a burst of MM-EVs carrying high levels of heparanase, which can eventually contribute to
promoting OCs differentiation. OCs in turn support MM cell growth and survival through the secretion
of IL-6 and osteopontin, finally favoring patients’ relapse [57].
ypoxic B (1–2 O2) conditions cause an increase in IL-32 expression in cells, hich is
associated ith poor survival and bone loss. Zahoor and colleagues reported that the infla atory
IL-32 can be delivered through -EVs, and plays a key role in pro oting OC activity [58]. ore
recently, Alessandro et al. [59] identified another protein delivered by MM-derived exosomes involved
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in osteoclastogenesis, epithelial growth factor receptor (EGFR) ligand amphiregulin (AREG). AREG
leads to the activation of EGFR in OC precursors, directly inducing their differentiation into mature OCs.
Moreover, AREG blocks MSC osteogenic differentiation and induces the release of the osteoclastogenic
cytokine IL-8. MM-derived exosomes further induce an imbalance between OCs and OBs by
reducing the MSC-mediated release of osteoprotegerin (OPG), and increasing that of RANKL in
an AREG-independent manner [59].
The evidence that MM-EVs not only support the formation of bone lesions by enhancing
OC activity, but also by inhibiting OB differentiation has been confirmed by several groups.
Zhang et al. demonstrated that MM-EVs inhibit osteogenesis of BM-mesenchymal stem cells in vitro
and exacerbate myeloma bone diseases in vivo [13]. Faict et al. showed that MM-EVs in the murine
model 5TGM1 cause the downregulation of Runt-related transcription factor 2 (RUNX2) and the
Wingless-related integration site (WNT) pathway, which positively regulate OB differentiation by
transferring inhibitors of the osteogenic pathways such as Dickkopf-1 (DKK-1) [60]. Furthermore,
Li and colleagues showed that RUNX2 can also be suppressed by MM-derived exosomes through
the transfer of the long non-coding RNA lncRUNX2-AS1 in mesenchymal stem cells. IN this context,
lncRUNX2-AS1 interferes with the splicing of RUNX2 repressing osteogenesis [61]. Of note, increasing
evidence supports the hypothesis that lncRNAs may represent a significant component of MM-EV
cargo, and may have a role in the communication between MM cells and the surrounding niche [14,62].
According to recent studies, miRNAs carried by cancer cell-derived EVs, i.e., miR-192 [63] and
miR-940 [64], also contribute to the OC–OB imbalance by promoting the differentiation of one cell
population at the expenses of the other [65]. Concerning MM, it has been reported that miR-21 enhances
the STAT3-dependent signaling by inhibiting PIAS3, thereby resulting in OC differentiation [66].
The miR-21 passenger strand (miR-21-3p), along with miR-103a-3p and miR-181a-3p involved in OB or
OC’ differentiation, have been found in EVs shed by the myeloma RPMI8226 cell line together with
protein regulators of bone lesions such as DKK-1, IL-7, and sFRP2 (secreted Frizzled Related Protein
2) [67,68].
7. MM-EVs Educate Bone Marrow Mesenchymal Cells
BM-MSCs play a major role in regulating micrometastasis growth, and MM cells have been
reported to educate BM-MSCs inducing a pro-tumor phenotype, thus resulting in the release of factors
that promote tumor survival, proliferation, migration [69], and osteoclastogenesis [70,71]. As illustrated
in Figure 4, EVs shed from MM cells and BM-MSCs are key players regulating micrometastasis growth.
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Recent work indicates that normal BM-MSC-derived exosomes (MSC-exosomes) display a
tumor suppressive potential due to the presence of tumor suppressive miRNAs, such as miR-15av,
largely consistent with their ability to promote tumor cell dormancy upon the initial micrometastasis
settlement [15]. A confirmation of the growth-inhibitory behavior of MSC-EVs has been reported in
bone metastatic breast cancer that shares the same BM microenvironment as MM and is in contact with
the same healthy MSC-EVs. Healthy MSC-EVs induce breast cancer cells to enter the G0/G1 phase
by upregulating tumor suppressive miRNAs such as miR-127, miR-197, miR-222, and miR-223 [72].
Similarly, miR-23b carried by EVs from BM mesenchymal stem cells of a human donor can induce
tumor cell dormancy in a bone marrow-metastatic human breast cancer cell line by suppressing a
gene, myristoylated alanine-rich C-kinase substrate (MARCKS), encoding a protein that promotes
cell proliferation and motility [73]. Although this tumor growth inhibitory mechanism activated by
MSC-EVs has not been studied in MM progression, reasonably it might also affect MM cell growth.
Indeed, miR-23b [74], miR-197 [75], and miR-223 [76], also play a tumor suppressor role in MM by
negatively regulating key oncogenes such as Mcl-1 and Notch2 [75,76].
On the other hand, the switch from micrometastasis to macrometastasis may be favored by MSC
preconditioning which promotes a pro-tumor activity of MSC-EVs. MM-EVs precondition BM-MSC
by promoting their viability via STAT3 and JNK phosphorylation [42].
Moreover, miRNAs carried by EVs derived from the MM cell line OPM-2—miR-146 and
miR-21—stimulate cytokine production in mesenchymal stem cells and their transformation into
carcinoma-associated fibroblasts (CAFs) [77]. In particular, changes induced by MM-EV-derived
miR-146a in BM-MSCs include Notch1 activation and the release of cytokines, in addition to chemokines
such as IL-6, IL-8, CXCL1, IP-10, CCL2, and CCL5, which favor MM cell growth, viability, and
migration [78,79].
As a result of MM-EV preconditioning, BM-MSCs can produce EVs (MM MSC-EVs). Normal
and MM BM-MSC-derived exosomes (MM MSC-exosomes) display different properties. In fact, while
the former hamper MM cell growth, MM MSC-exosomes are able to promote MM cell proliferation
and dissemination, due to the selective transfer of key cytokines, such as IL-6 and CCL2, or junction
plakoglobin and fibronectin that may increase MM cell adhesive ability [15].
8. The Dual Effect of MM-EVs in Anti-Tumor Immunity and Immune Escape
The ability of tumor cells to escape the immune system control is a key event in tumor progression.
During the metastatic process, tumor cells leave the immunosuppressed primary site to reach the
metastatic site. During the metastatic journey and settlement at distant sites, cancer cells are more
exposed to the anti-tumor immune system attack [80].
During tumor progression, cancer-derived EVs have a dual role, acting both as immune suppressors
or immune promoters. Tumor-derived EVs can trigger the anti-tumor response [81] since they carry
tumor antigens that can be taken up by dendritic cells and presented to T cells, thereby triggering
their activation [82]. Other immune activating mechanisms rely on EV cytokine content, i.e., IL-15
and IL-18 that promote NK cell cytotoxicity and proliferation [83], or the expression of heat shock
protein 70 (Hsp70) able to switch regulatory T cells (TReg) into T helper 17 cells (Th17) and inhibit
tumor growth [81].
Several groups have demonstrated the potential role of cancer-derived EVs in suppressing the
immune responses against different types of cancers mediated by NK and CD8+ T cells [84–86]; creating
an immunosuppressive pro-tumor environment by expanding the TRegs population [87], stimulating
M2 macrophage polarization [88] and dendritic cell tolerance [89,90]; or by suppressing CTL response
through PD-L1 delivery [91].
The first observation in multiple myeloma is that MM-EVs are able to carry several pro- and
anti-inflammatory cytokine and chemokines, i.e., IL-6, CCL2 [15], IL-15 [83], IL-7 [67], IL-32 [58],
IL-10 and IL-16 [92], and VEGF [42]. MM-EVs may also contribute to changing the cytokine milieu,
by favoring BM-MSC-mediated release of cytokines and chemokines such as IL-6, CXCL1, IP-10,
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CCL5 [78], and IL-8 [59]. Although all these cytokines are well known players in inflammatory
and immune response, the overall immune modulating effects of MM-EVs in the myeloma setting
require clarification.
On the one end, MM-EVs can be potential activators of the anti-tumor immune response since
they carry on their surface the same tumor-specific or tumor-associated antigens as the donor MM cells.
Indeed, it has been demonstrated that EV-derived tumor antigens can induce the activation of dendritic
cells that in turn stimulate the autologous anti-tumor T-cell responses [82]. Leaf and colleagues
reported that MM-specific antigens, such as MUC-1 and survivin, can be delivered by MM-EVs to
the surrounding APCs, thus inducing their activation. MM-EVs carry the specific immunoglobulin
produced by the malignant plasma cells of origin. This represents a unique antigenic determinant
(idiotype), which may serve as a tumor-specific antigen [93,94]. Furthermore, Caivano et al. found that
EVs from myeloma patients express CD38, a recognized tumor-associated antigen, which is the target
of recent immunotherapeutic approaches [95].
Interestingly, the immunogenic activity of MM-EVs (Figure 5A) can be potentiated by inflammatory
stimuli or pharmacological treatment.
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Indeed, Xie et al. demonstrated that EVs produced by M cells previously engineered to
overexpr ss TNF-α can e hance the CD8+ T l cyte response in ivo preventing tumor growth
after subcutaneously challenging mice i munized with MM-EVs. These data uggest that inflammatory
cytokine sti uli can enhance EV immu ogenic activity [96]. Similarly, pharmacological treatments
may promote MM-EV i mune activating effect. Indeed, treatment with melphalan increases the
capability of MM cells to release exosomes that can activate the NF-κB pathway in NK cells, inducing
them to produce IFN-γ [81]. Interestingly, upon stimulation with doxorubicin and melphalan, MM
cells and MM-derived exosomes show increased expression of the IL-15/IL15RA complex allowing the
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functional trans-presentation of IL-15 to neighboring NK cells, with the consequent induction of their
activation and proliferation [83].
EVs produced in the tumor microenvironment have been reported to hamper the immune
surveillance and play a key role in tumor progression [97]. According to recent studies,
immunosuppressive MDSCs accumulate in the BM in the early stages as one of the most prominent
immune populations involved in MM progression by suppressing T cell activation and inducing MM cell
survival [98]. As a consequence, high levels of MDSC activity promote tumor development [99]. Wang
and colleagues demonstrated that MM-MSC-exosomes contribute an important immunosuppressive
effect by activating MDSCs [42]. BM MSC-exosomes induce MDSC expansion and survival by
activating STAT3 and STAT1 pathways and increasing the anti-apoptotic proteins Bcl-XL and Mcl-1 [42].
Moreover, on a functional level, these exosomes enhance MDSC production of inducible nitric oxide
and the suppression of T cell activation (Figure 5B) [42].
Although studying the complex role of EVs in the modulation of immune responses during
MM has provided the first exciting results, in order to understand which elements affect EV immune
suppressive or immune stimulating behavior, it is crucial to expand the knowledge on the effects of EVs
on other immune cell players in the context of this disease, including NK cells, cytotoxic T lymphocytes,
T regulatory cells, Th17 cells, dendritic cells, tumor associated macrophages, granulocytes, etc. [100].
Overall, the reported lines of evidence demonstrate how EV contribution is crucial during all the
different steps of MM progression, and provide the rationale for further studies aimed at achieving a
better understanding of the dynamics involving EV-mediated communication with the premetastatic
niche, and during the settlement and growth of new bone lesions. This will allow us to define the
molecular basis underlying the crosstalk between MM cells, the surrounding microenvironment, and
the metastatic niche, to identify new molecular therapeutic targets in order to improve the final outcome
of this disease.
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